Probing gut-brain links in Alzheimer's disease with rifaximin

Area of Science:

• Neuroscience
• Microbiology
• Gastroenterology

Background:

• Gut-microbiome-inflammation interactions are implicated in neurodegenerative diseases like Alzheimer's disease (AD).
• Rifaximin, a gut-specific antibiotic, may modulate neurodegeneration by altering gut microbiota and reducing inflammation.

Purpose of the Study:

• To investigate the effects of rifaximin on neurodegenerative markers and gut microbiota in patients with mild to moderate probable AD dementia.
• To explore the potential of rifaximin as a therapeutic agent for Alzheimer's disease by targeting the gut microbiome.

Main Methods:

• A pilot, open-label trial involving 10 subjects with mild to moderate probable AD dementia.
• Treatment with rifaximin for 3 months.
• Assessment of serum neurofilament-light, phosphorylated tau (pTau)181, glial fibrillary acidic protein (GFAP), cytokines (IL-6, IL-13), and fecal microbiota composition.

Main Results:

• Significant reduction in serum neurofilament-light levels (P < .004).
• Significant increase in fecal phylum Firmicutes.
• Non-significant reductions in serum pTau181 and GFAP, and trends towards lower IL-6 and IL-13.
• Correlation between increased stool Erysipelatoclostridium and reduced serum pTau181/GFAP.

Conclusions:

• Rifaximin treatment demonstrated a significant reduction in a key neurodegeneration marker in AD patients.
• The study suggests a potential role for gut microbiota modulation in Alzheimer's disease.
• Results support the design of larger, placebo-controlled trials to confirm rifaximin's efficacy.